Investors fund Prometheus team's 'unfinished business' with $400M for new inflammatory biotech Mirador

Having some free time following the $10.8 billion buyout of Prometheus Biosciences made Mark McKenna realize he had some “unfinished business.”

Prometheus had managed to create a therapeutic that improved efficacy in inflammatory bowel disease from about 15% to over 25%. But what about the other 75%?